GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMY) » Definitions » Cyclically Adjusted PS Ratio

NVZMY (Novonesis (Novozymes) B) Cyclically Adjusted PS Ratio : (As of Jan. 18, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Chart

Novonesis (Novozymes) B Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.61 7.82 11.24 6.49 6.55

Novonesis (Novozymes) B Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.33 5.73 5.05 6.55 -

Competitive Comparison of Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio falls into.



Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novonesis (Novozymes) B's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Novonesis (Novozymes) B's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0/118.5000*118.5000
=0.000

Current CPI (Jun. 2024) = 118.5000.

Novonesis (Novozymes) B Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.763 99.700 2.095
201409 1.754 99.700 2.085
201412 1.687 99.400 2.011
201503 1.667 100.200 1.971
201506 1.671 100.300 1.974
201509 1.715 100.200 2.028
201512 1.637 99.800 1.944
201603 1.762 100.200 2.084
201606 1.701 100.600 2.004
201609 1.688 100.200 1.996
201612 1.774 100.300 2.096
201703 1.798 101.200 2.105
201706 1.794 101.200 2.101
201709 1.941 101.800 2.259
201712 1.956 101.300 2.288
201803 1.974 101.700 2.300
201806 1.871 102.300 2.167
201809 1.958 102.400 2.266
201812 1.953 102.100 2.267
201903 1.823 102.900 2.099
201906 1.817 102.900 2.092
201909 1.912 102.900 2.202
201912 1.954 102.900 2.250
202003 1.977 103.300 2.268
202006 1.791 103.200 2.057
202009 1.929 103.500 2.209
202012 2.009 103.400 2.302
202103 2.152 104.300 2.445
202106 2.066 105.000 2.332
202109 2.127 105.800 2.382
202112 2.080 106.600 2.312
202203 2.316 109.900 2.497
202206 2.179 113.600 2.273
202209 2.088 116.400 2.126
202212 2.304 115.900 2.356
202303 2.392 117.300 2.416
202306 2.208 116.400 2.248
202309 2.291 117.400 2.312
202312 2.449 116.700 2.487
202406 0.000 118.500 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novonesis (Novozymes) B  (OTCPK:NVZMY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novonesis (Novozymes) B Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

From GuruFocus

Q3 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2022 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2020 Novozymes A/S Trading Update Call Transcript

By GuruFocus Research 02-14-2024

Novozymes A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Novozymes A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024